Topical Flucytosine Formulations with pH Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complicated vulvovaginal candidiasis (VVC) are ineffective due to high rates of relapse and the development of drug-resistant Candida species, and existing antifungal agents pose significant side effects and risks of resistance.
Innovation Solution
Topical formulations of flucytosine with controlled systemic absorption, using pH modulators and hydrophilicity modulators to minimize transdermal or transmucosal penetration, combined with other antifungal agents to maximize local efficacy while limiting systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical formulations of flucytosine are used to treat resistant Candida strains, then local efficacy is improved, but systemic absorption and side effects increase
Solution Approach 1:
The patent modifies the physical and chemical parameters of flucytosine through pH modulation and hydrophilicity modulation. By adjusting pH to specific ranges and using hydrophilicity modulators, the formulation controls the ionization state and membrane permeability of flucytosine, thereby reducing transdermal and transmucosal absorption while maintaining local therapeutic efficacy at the infection site.
Solution Approach 2:
The patent introduces pH modulators and hydrophilicity modulators as intermediary substances that mediate between flucytosine and the biological membranes. These modulators create a controlled interface that allows flucytosine to remain effective locally while preventing excessive systemic absorption through pH-dependent ionization and hydrophilicity-based membrane interaction control.
2Reliability
If maintenance suppressive azole regimens are used for recurrent VVC, then initial treatment success is improved, but relapse rate increases
Solution Approach 1:
The patent changes the pharmacological parameters by using flucytosine instead of azole antifungals. Flucytosine has different mechanisms of action and resistance profiles, and when combined with pH and hydrophilicity modulation, achieves effective local treatment with reduced relapse rates compared to traditional azole maintenance regimens.
Solution Approach 2:
The patent creates a composite formulation combining flucytosine with pH modulators and hydrophilicity modulators. This composite approach synergistically enhances local efficacy while controlling systemic absorption, providing a more effective long-term treatment solution for recurrent VVC compared to single-agent azole regimens.
3Reliability
If oral flucytosine is used to treat serious systemic infections, then therapeutic efficacy is improved, but systemic side effects increase
Solution Approach 1:
The patent extracts the active pharmaceutical ingredient (flucytosine) from systemic circulation by formulating it topically with controlled absorption properties. Through pH modulation and hydrophilicity modulation, the formulation ensures flucytosine remains primarily localized at the infection site, extracting it from the systemic circulation pathway while maintaining therapeutic efficacy.
Solution Approach 2:
The patent applies local quality by creating a formulation that provides high concentration of flucytosine specifically at the site of infection while minimizing systemic distribution. The pH and hydrophilicity modulators ensure the drug remains localized, providing intense local therapeutic effect without the broad systemic side effects associated with oral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations effectively treat resistant strains of Candida spp. with reduced side effects and lower potential for resistance development, maintaining high local drug levels at the infection site without systemic absorption.
Implementation Method 1
a significant portion of the active drug is ionized, and therefore rendered less capable of transdermal or transmucosal penetration
Implementation Method 2
hydrophilicity modulators to minimize transdermal or transmucosal penetration
Data Source
AI summary
The invention relates to topical formulations of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of Candida spp., especially C. albicans, C. glabrata, and C. tropicalis, and which pose limited risk of side effects, adverse reactions, or the development of resistant pathogens. The invention provides novel topical formulations of flucytosine designed to allow the active drug to act at the local application area, but which inhibit or moderate transdermal or transmucosal absorption of the drug, thus limiting systemic exposure.